Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer.
Future Oncol
; 15(34): 3895-3907, 2019 Dec.
Article
em En
| MEDLINE
| ID: mdl-31621403
ABSTRACT
Aim:
EGFR-tyrosine kinase inhibitors (TKIs) vary in efficacy, side effects (SEs) and dosing regimen. We explored EGFR-TKI treatment attribute preferences in EGFR mutation-positive metastatic non-small-cell lung cancer. Materials &methods:
Patients completed a survey utilizing preference elicitationmethods:
direct elicitation of four EGFR-TKI profiles describing progression-free survival (PFS), severe SE risk, administration; discrete choice experiment involving 12 choice tasks.Results:
90 participated. The preferred profile (selected 89% of times) had the longest PFS (18 months) and the lowest severe SE risk (5%). Patients would need compensation with ≥three-times longer PFS for severe SEs. Patients would accept ≤7 months PFS reduction for oral treatments versus intravenous.Conclusion:
Patients preferred longer PFS but were willing to accept reduced PFS for more favorable SEs and dosing convenience.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores de Proteínas Quinases
/
Preferência do Paciente
/
Neoplasias Pulmonares
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Qualitative_research
/
Risk_factors_studies
Limite:
Aged80
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article